The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
| Autor: | Kenneth Newman, Dave Singh, Thomas Bengtsson, Katharine Abbott-Banner |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male medicine.drug_class Pyrimidinones Placebo 03 medical and health sciences Pulmonary Disease Chronic Obstructive 0302 clinical medicine Double-Blind Method Bronchodilator Forced Expiratory Volume Administration Inhalation Medicine Humans Lung volumes Albuterol Metered Dose Inhalers Tiotropium Bromide Lung Aged COPD Cross-Over Studies Inhalation business.industry Ipratropium respiratory system Middle Aged medicine.disease Isoquinolines Crossover study United Kingdom respiratory tract diseases Bronchodilator Agents Treatment Outcome 030228 respiratory system 030220 oncology & carcinogenesis Anesthesia Salbutamol Drug Therapy Combination Female business medicine.drug circulatory and respiratory physiology |
| Zdroj: | Singh, D, Abbott-Banner, K, Bengtsson, T & Newman, K 2018, ' The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD ', European Respiratory Journal, vol. 52, no. 5, 1801074 . https://doi.org/10.1183/13993003.01074-2018 |
| ISSN: | 1399-3003 |
| DOI: | 10.1183/13993003.01074-2018 |
| Popis: | We investigated the short-term bronchodilator effects of RPL554 (an inhaled dual phosphodiesterase 3 and 4 inhibitor) combined with other bronchodilators in chronic obstructive pulmonary disease patients with reversibility (>150 mL to short-acting bronchodilators).Study 1 was a six-way, placebo-controlled crossover study (n=36) with single doses of RPL554 (6 mg), salbutamol (200 µg), ipratropium (40 µg), RPL554 (6 mg)+salbutamol (200 µg), RPL554 (6 mg)+ipratropium (40 µg) or placebo. Study 2 was a three-way crossover study (n=30) of tiotropium (18 µg) combined with RPL554 (1.5 or 6 mg) or placebo for 3 days. Forced expiratory volume in 1 s (FEV1), lung volumes and specific airway conductance (sGaw) were measured.In study 1, peak FEV1 change compared with placebo was similar with RPL554, ipratropium and salbutamol (mean 223, 199 and 187 mL, respectively). The peak FEV1 was higher for RPL554+ipratropium versus ipratropium (mean difference 94 mL; pversus salbutamol (mean difference 108 mL; p1 effects than placebo. The average FEV1(0–12 h) increase was greater with RPL554 6 mg only versus placebo (mean difference 65 mL; p=0.0009). In both studies, lung volumes and sGaw showed greater RPL554 combination treatment effects versus monotherapy.RPL554 combined with standard bronchodilators caused additional bronchodilation and hyperinflation reduction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|